Drug Coated Balloons Impact of Coating Formulation and
Drug Coated Balloons Impact of Coating Formulation and Antiproliferative Choices on Drug Transfer and Tissue Pharmacokinetics Bruno Scheller Klinische und Experimentelle Interventionelle Kardiologie, Universität des Saarlandes, Campus Homburg Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes Homburg / Saar, Germany
Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company • Grant/Research Support • B. Braun • Speaker Honoraria • B. Braun, Invatec Medtronic • Major Stock Shareholder/Equity • Inno. Ra Gmb. H (a small company doing research in local drug delivery) • Intellectual Property Rights • Named as coinventor of a patent application submitted by Charite university hospital, Berlin, Germany
Paclitaxel Binding to Hydrophobic Sites within Arterial Tissue Ex vivo perfusion of calf carotid arteries, transmural distribution protein binding serum proteins raise paclitaxel levels in solution, but hinder distribution through tissues Creel, Circ Res 2000; 86: 879 -884 Lovich, J Pharm Sci 2001; 90: 1324 -1335
Reaches adjacent segments Additional device/step Technology complex Handling needs training Genie®, Acrostak, SUI Dommke, Thromb Haemost 2007; 98: 674– 680 Herdeg, Clin Res Cardiol 2008; 97: 49 - 52
X-ray Contrast Media for Local Drug Delivery Paclitaxel Iopromide (Ultravist®) Invest Radiol 2002; 37: 29 -34, Eur Heart J 2003; 24: 1462 -7, J Am Coll Cardiol 2003; 42: 1415 -20
Euro. Intervention 2011; 7: K 32 -42
X-ray contrast media for local drug delivery Paclitaxel in Iopromide (Ultravist®) – tissue levels Scheller, J Am Coll Cardiol 2003; 42: 1415 -20 Speck, Invest Radiol 2004; 39: 182 -6
Circulation 2010; 121: 2672 -80
Prototype Drug Coated Balloon non-coated Paccocath coated
DEB + stent - porcine coronary model EEE Paclitaxel Ac Paclitaxel Iopromide Circulation 2004; 110: 810 -4
Excipient Governs Efficacy Restenosis at 4 Weeks (porcine coronary overstretch model) 100% Percent of Control Late Lumen Loss (%) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% POBA Control NO Additive J Additive K Additive L Different Additives, Same Dose of Paclitaxel Data obtained from Lutonix, 2009
Roughened Balloon Surface vs. Matrix Coating – Paclitaxel Iopromide Control DIOR®I PACCOCATH® Cremers, Clin Res Cardiol 2009; 98: 325– 330
Overdosing and Balloon Inflation Time Paclitaxel 5 µg/mm², 28 days follow-up, n=56 Cremers, Thromb Haem 2009; 101: 201 -6
Cremers, Clin Res Cardiol. 2012 Jan 12. [Epub ahead of print]
Speck, Circulation: Cardiovasc Int 2012, submitted
Speck, Circulation: Cardiovasc Int 2012, submitted
Speck, Circulation: Cardiovasc Int 2012, submitted
Speck, Circulation: Cardiovasc Int 2012, submitted
Waksman, Circ Cardiovasc Intervent. 2009; 2: 352 -8
SCAAR registry Clinical restenosis after 6 months: 4 vs. 13% (de-novo and ISR) SCAAR report, Sweden, 2010
Coronary SVD – Dior. TM I, Se. Quent. TM Please Heart 2010; 96: 1291 -6 Clin Res Cardiol 2010; 99: 165– 174 Euro. Intervention 2011; 7: K 57 -60
Coronary de novo DCB + BMS – Elutax. TM, Se. Quent. TM Please Liistro, TCT 2011 Wöhrle, Heart 2011; 97: 1338 -42
SFA – Paccocath. TM, Moxy. TM, In. Pact. TM Werk, CIRSE 2011
Euro. Intervention 2011; 7: K 17 -22
Circ Cardiovasc Interv. 2011; 4: 447 -55
Cremers, Clin Res Cardiol. 2012 Feb 1. [Epub ahead of print]
Circulation 2010; 121: 2672 -80
DCB - Sirolimus Scheller B, Speck U, et al. 2009; patent application published by Dadino RC, Zjao JZ. US 2010/0331816
Impact of Coating Formulation and Antiproliferative Choices on Drug Transfer and Tissue Pharmacokinetics Preclinical data o Not all drug coated balloon catheters are equally effective o Pure drug on the balloon not effective o Key role of additives o Ptx may work with different additives o Conflicting results with ‘limus’ Clinical data o Limited to ptx o No sufficient data basis to directly compare different DCB o Positive RCT coronary from ptx iopromide coated balloons o Positive RCT SFA from ptx with different additives (iopromide, undisclosed, urea)
- Slides: 29